protein synthesis in tils
Adoptive T cell therapy aims to transfer a patient's own TILs back to the patient - after clinical scale expansion - to fight tumor. This type of therapy has been largely ineffective as re-introduced TILs do not thrive/ survive well in patients. Modulation of TIL metabolism prior to re-introduction is a viable strategy to promote TIL persistence. We are studying the role of protein synthesis in TILs and have found that it compromises T cell persistence in tumors. Protein synthesis inhibition in adoptively transferred TILs has the power to cause complete tumor regression.